| James E Turek, MD | |
|
2347 Hwy 17 Bus S, Garden City, SC 29576-7611 | |
| (843) 357-2443 | |
| (843) 357-2132 |
| Full Name | James E Turek |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 37 Years |
| Location | 2347 Hwy 17 Bus S, Garden City, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942360672 | NPI | - | NPPES |
| 141965 | Medicaid | SC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 14196 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Amedisys Home Health Of Myrtle Beach | Myrtle beach, SC | Home health agency |
| Amedisys Home Health Of Georgetown | Georgetown, SC | Home health agency |
| Kindred At Home | Myrtle beach, SC | Home health agency |
| Well Care Home Health Of The Lowcountry Inc | Myrtle beach, SC | Home health agency |
| Tidelands Waccamaw Community Hospital | Murrells inlet, SC | Hospital |
| Tidelands Georgetown Memorial Hospital | Georgetown, SC | Hospital |
| Grand Strand Regional Medical Center | Myrtle beach, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Georgetown Physician Associates, Llc | 2365697398 | 149 |
News Archive
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, announced that for the second quarter ended June 30, 2010, income from continuing operations increased to $195 million, or $1.07 per diluted share, compared to $188 million, or $1.00 per diluted share, in the second quarter of 2009. Results for 2009 included a benefit associated with an insurance recovery of $0.05 per share, offset by charges of $0.04 per share associated with the company's debt repurchase and an investment writeoff.
Giving women with early breast cancer a drug called gefitinib (Iressa) before surgery could reduce the size of their tumours, suggests a randomised trial published online today by The Lancet Oncology.
A new Canadian Medical Association report on health-care transformation was met with a mix of optimism and concern by the Canadian Nurses Association.
Everyone hopes that one day stem cell-based regenerative medicine will help repair diseased tissue. Before then, it may be necessary to decipher the epigenetic signals that give stem cells their unique ability to self-renew and transform them into different cell types.
› Verified 1 days ago
| Entity Name | Access Medical Management, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154415933 PECOS PAC ID: 6406924000 Enrollment ID: O20081009000411 |
News Archive
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, announced that for the second quarter ended June 30, 2010, income from continuing operations increased to $195 million, or $1.07 per diluted share, compared to $188 million, or $1.00 per diluted share, in the second quarter of 2009. Results for 2009 included a benefit associated with an insurance recovery of $0.05 per share, offset by charges of $0.04 per share associated with the company's debt repurchase and an investment writeoff.
Giving women with early breast cancer a drug called gefitinib (Iressa) before surgery could reduce the size of their tumours, suggests a randomised trial published online today by The Lancet Oncology.
A new Canadian Medical Association report on health-care transformation was met with a mix of optimism and concern by the Canadian Nurses Association.
Everyone hopes that one day stem cell-based regenerative medicine will help repair diseased tissue. Before then, it may be necessary to decipher the epigenetic signals that give stem cells their unique ability to self-renew and transform them into different cell types.
› Verified 1 days ago
| Entity Name | Georgetown Physician Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235475930 PECOS PAC ID: 2365697398 Enrollment ID: O20130225000067 |
News Archive
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, announced that for the second quarter ended June 30, 2010, income from continuing operations increased to $195 million, or $1.07 per diluted share, compared to $188 million, or $1.00 per diluted share, in the second quarter of 2009. Results for 2009 included a benefit associated with an insurance recovery of $0.05 per share, offset by charges of $0.04 per share associated with the company's debt repurchase and an investment writeoff.
Giving women with early breast cancer a drug called gefitinib (Iressa) before surgery could reduce the size of their tumours, suggests a randomised trial published online today by The Lancet Oncology.
A new Canadian Medical Association report on health-care transformation was met with a mix of optimism and concern by the Canadian Nurses Association.
Everyone hopes that one day stem cell-based regenerative medicine will help repair diseased tissue. Before then, it may be necessary to decipher the epigenetic signals that give stem cells their unique ability to self-renew and transform them into different cell types.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James E Turek, MD 2347 Hwy 17 Business South, Garden City, SC 29576-7611 Ph: (843) 357-2443 | James E Turek, MD 2347 Hwy 17 Bus S, Garden City, SC 29576-7611 Ph: (843) 357-2443 |
News Archive
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, announced that for the second quarter ended June 30, 2010, income from continuing operations increased to $195 million, or $1.07 per diluted share, compared to $188 million, or $1.00 per diluted share, in the second quarter of 2009. Results for 2009 included a benefit associated with an insurance recovery of $0.05 per share, offset by charges of $0.04 per share associated with the company's debt repurchase and an investment writeoff.
Giving women with early breast cancer a drug called gefitinib (Iressa) before surgery could reduce the size of their tumours, suggests a randomised trial published online today by The Lancet Oncology.
A new Canadian Medical Association report on health-care transformation was met with a mix of optimism and concern by the Canadian Nurses Association.
Everyone hopes that one day stem cell-based regenerative medicine will help repair diseased tissue. Before then, it may be necessary to decipher the epigenetic signals that give stem cells their unique ability to self-renew and transform them into different cell types.
› Verified 1 days ago
Shelia Fankhauser, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 2347 Hwy 17 Bus S, Garden City, SC 29576 Phone: 843-357-2443 Fax: 843-357-2132 |